BPRDP 056
Alternative Names: BPRDP-056; T-1201Latest Information Update: 19 Sep 2025
At a glance
- Originator Molecular Targeting Technologies; National Health Research Institutes
- Developer Taivex Therapeutics
- Class Amines; Antineoplastics; Camptothecins; Drug conjugates; Indolizines; Pyrans; Quinolines; Small molecules; Zinc compounds
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 19 Sep 2025 Phase-I clinical development for Solid tumours (Late-stage disease) is underway in Taiwan (IV) (NCT04866641)
- 28 Feb 2025 Adverse events data from preclinical trials in Solid tumours released by Taivex Therapeutics
- 28 Feb 2025 Taivex Therapeutics plans a phase II trial for Solid tumours (IV)